Details

Autor(en) / Beteiligte

• Weitz, Jeffrey I
• Lensing, Anthonie W.A
• Prins, Martin H
• Bauersachs, Rupert
• Beyer-Westendorf, Jan
• Bounameaux, Henri
• Brighton, Timothy A
• Cohen, Alexander T
• Davidson, Bruce L
• Decousus, Hervé
• Freitas, Maria C.S
• Holberg, Gerlind
• Kakkar, Ajay K
• Haskell, Lloyd
• van Bellen, Bonno
• Pap, Akos F
• Berkowitz, Scott D
• Verhamme, Peter
• Wells, Philip S
• Prandoni, Paolo

Titel

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Ist Teil von

• The New England journal of medicine, 2017-03, Vol.376 (13), p.1211-1222

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• In this study involving nearly 3400 patients with venous thromboembolism, both prophylactic and therapeutic doses of rivaroxaban were superior to aspirin in reducing the risk of recurrent thromboembolism with a similar risk of bleeding. Venous thromboembolism, which includes deep-vein thrombosis and pulmonary embolism, is the third most common cause of vascular death after myocardial infarction and stroke. 1 – 3 The mainstay of treatment is anticoagulation, 4 and in patients without active cancer, guidelines suggest the use of direct oral anticoagulant agents such as rivaroxaban over vitamin K antagonists such as warfarin. 4 Anticoagulation therapy is administered for 3 months or longer, depending on the balance between the risk of recurrent venous thromboembolism and the risk of bleeding. 4 In patients without reversible risk factors, the risk of recurrent venous thromboembolism is as much as 10% in the first . . .